(Press-News.org) DENVER — Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.
This is possible, the researchers from AVEO Pharmaceuticals, Inc. said, because they have used a new way of creating animal tumor models that mimic tumor variation seen in human. Based on the results of these studies, they have found a single biomarker that may predict resistance to tivozanib, an oral, triple VEGF (vascular endothelial growth factor) receptor inhibitor.
Tivozanib is in an ongoing Phase III registration trial in kidney cancer, which recently completed enrollment of 500 patients ahead of schedule, and is in multiple early trials in patients with breast, colon and lung cancer.
In a study being presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, the researchers said that the biomarker reflects the presence of certain white blood cells inside a tumor.
"Predictive biomarkers that can be used to assess activity of treatments are what we are all striving for in cancer therapy today," said Murray Robinson, Ph.D., senior vice president, translational medicine, at AVEO Pharmaceuticals, Inc., in Cambridge, Mass. "We want to know in advance which patients are most likely to respond to an anticancer therapy, and in this way, spare patients who cannot respond from ineffective therapy."
In its ongoing trials, the company is collecting biomarker data in order to correlate the presence of the biomarker with clinical activity. "This is a necessary step that we must do to validate the predictive value of the biomarker," Robinson said.
To date, the researchers have evaluated 600 human tumor samples across eight different tumor types.
"We saw the biomarker in subsets of all the human tumor types we looked at. Based on these findings, we believe that the biomarker discovered in our animal models may be replicated in human tumors, and may be an important discovery relevant to patient care," said Robinson.
At the AACR conference, Robinson showed that the same biomarker identified in AVEO's breast tumor model was associated with clinical activity in a set of kidney tumor patients from a previous Phase II kidney cancer trial. This biomarker is associated with white blood immune cells that are recruited into the tumor to produce angiogenic growth factors.
"This produces an intrinsic resistance to tivozanib, which is an anti-angiogenesis agent," Robinson said.
The researchers inserted specific oncogenes and other engineered genes altered in numerous cancer types into the tissue of animals and then studied the variety of tumors that were produced. For example, genetically altering the HER2 gene resulted in tumors that naturally expressed different pathways for growth, Robinson said.
"That mimics what happens in women with HER2-positive breast cancer because across patients, there is a significant variation in these HER2 tumors that dramatically alters their response to treatment," he said.
After molecularly characterizing each tumor, they tested what happened when the cancer was treated.
"Because we have the molecular character of the tumor, we can associate biology with response. We have an ongoing effort to discover and develop predictive biomarkers that will aid our clinical development strategies and, we believe, maximize the benefit for specific patient populations," Robinson said.
In this way the researchers isolated tumors that do not respond to tivozanib, and from this they were able to identify the resistant biological phenotype. Further study revealed a correlation between the biomarkers and tivozanib clinical activity.
###
Follow the AACR on Twitter: @AACR #AACR
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists, providing a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
END
DENVER — A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.
"We are making progress toward the goal of understanding how drugs work in different individuals," said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine. "Using new technologies makes it possible to measure effects of therapeutic agents in tumor cells and different cell populations within our patients. Now that we can make these measurements, we are one step closer to being able to ...
DENVER — Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests.
"Measuring expressions of microRNA in bodily fluid represents a very promising tool with widespread implications for screening," said Liana Adam, M.D., Ph.D., assistant professor in urology at The University of Texas MD Anderson Cancer Center.
Adam presented her findings at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic ...
DENVER — Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
HCC is the most common primary malignant tumor of the liver; c-Met is a receptor for hepatocyte growth factor that appears to drive liver cancer growth, invasion and metastasis.
"Current therapies for HCC patients are 'one size fits all.' We propose ...
Detection of acute HIV infection (the stage of disease immediately after HIV acquisition but before HIV antibodies are detectable) with pooled nucleic acid amplification testing (that detects the presence of HIV genetic material in the blood before antibodies are detectable) is feasible but not cost-effective in all settings. Rather, pooled nucleic acid amplification testing after testing for antibodies with third-generation enzyme immunoassays (which can detect the first antibody to appear after infection) or rapid testing is only cost-effective when targeted to settings ...
In research published this week in PLoS Medicine, Vincent Gajdos and colleagues report the results of a randomized trial conducted among hospitalized infants with bronchiolitis. The researchers enrolled nearly 500 children aged 15 days to 2 years who were admitted to seven French hospitals for a first episode of acute bronchiolitis. Their results show that a physiotherapy technique (increased exhalation and assisted cough) commonly used in France does not reduce time to recovery in this population. The researchers conclude "Our results did not support the recommendation ...
Biologists from The University of Texas at Arlington have uncovered virus fragments from the same family of the modern Hepatitis B virus locked inside the genomes of songbirds such as the modern-day zebra finch. The article, publishing next week in the online, open access journal PLoS Biology, marks the first time that endogenous hepadnaviruses have been found in any organism. An endogenous virus is one that deposits itself or fragments of itself into the chromosome of an organism, allowing it to be passed from generation-to-generation. Previously, most of these known "fossilized" ...
PHOENIX, Ariz. — Sept. 28, 2010 — The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Arizona Cancer Center, Mayo Clinic and the Translational Genomics Research Institute (TGen).
Targeting INPP5A could provide physicians with better ways to prevent and treat cutaneous squamous cell carcinoma, or SCC, a skin cancer that often spreads to other parts of the body, according to a scientific paper published today in the journal Cancer Prevention Research.
"Loss ...
WASHINGTON, DC – September 28, 2010 -- Now that the H1N1 influenza pandemic is officially over, what will happen to the virus? In a perspective article published today in the online open-access journal mBio®, scientists from the National Institutes of Health delve into history and explore the fates of other pandemic influenza viruses in order to speculate on the future of the most recent pandemic virus.
"While human influenza viruses have often surprised us, available evidence leads to the hope that the current pandemic virus will continue to cause low or moderate mortality ...
MEDFORD/SOMERVILLE, Mass. – Sodium gets a bad rap for contributing to hypertension and cardiovascular disease. Now biologists at Tufts University's School of Arts and Sciences have discovered that sodium also plays a key role in initiating a regenerative response after severe injury. The Tufts scientists have found a way to regenerate injured spinal cord and muscle by using small molecule drugs to trigger an influx of sodium ions into injured cells.
The approach breaks new ground in the field of biomedicine because it requires no gene therapy; can be administered after ...
In this week's PLoS Medicine, the Editors argue that drug companies should be held much more accountable for their human rights responsibilities to make medicines available and accessible to those in need. Despite decades of advocacy on the part of the access to medicines movement, and human rights guidelines developed in 2008 for pharmaceutical companies that make clear that their responsibilities go beyond stakeholder value to encompass human rights, there is inadequate accountability, say the Editors. "At the same time that the 825 billion dollar global pharmaceutical ...
